aTYR PHARMA Total Assets Growth & History (ATYR)
aTYR PHARMA's total assets was $93.0M for fiscal 2025.
View full aTYR PHARMA company overviewaTYR PHARMA annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $93.0M | −$3.8M | −3.95% |
| 2024 | 2024-12-31 | $96.8M | −$23.8M | −19.75% |
| 2023 | 2023-12-31 | $120.7M | $24.9M | +25.96% |
| 2022 | 2022-12-31 | $95.8M | −$19.8M | −17.09% |
| 2021 | 2021-12-31 | $115.5M | $76.8M | +198.34% |
| 2020 | 2020-12-31 | $38.7M | $2.5M | +7.01% |
| 2019 | 2019-12-31 | $36.2M | −$16.6M | −31.39% |
| 2018 | 2018-12-31 | $52.7M | −$36.6M | −40.97% |
| 2017 | 2017-12-31 | $89.4M | $8.8M | +10.97% |
| 2016 | 2016-12-31 | $80.5M | −$49.2M | −37.90% |
| 2015 | 2015-12-31 | $129.7M | $109.0M | +528.15% |
| 2014 | 2014-12-31 | $20.6M | — | — |
aTYR PHARMA quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $69.8M | −$31.7M | −31.23% |
| Q1 2026 | 2026-03-31 | $79.7M | −$17.6M | −18.09% |
| Q4 2025 | 2025-12-31 | $93.0M | −$3.8M | −3.95% |
| Q3 2025 | 2025-09-30 | $106.7M | $15.0M | +16.41% |
| Q2 2025 | 2025-06-30 | $101.5M | −$4.4M | −4.16% |
| Q1 2025 | 2025-03-31 | $97.2M | −$16.0M | −14.13% |
| Q4 2024 | 2024-12-31 | $96.8M | −$23.8M | −19.75% |
| Q3 2024 | 2024-09-30 | $91.6M | −$33.5M | −26.75% |
| Q2 2024 | 2024-06-30 | $105.9M | −$26.8M | −20.19% |
| Q1 2024 | 2024-03-31 | $113.3M | −$23.6M | −17.24% |
| Q4 2023 | 2023-12-31 | $120.7M | $24.9M | +25.96% |
| Q3 2023 | 2023-09-30 | $125.1M | $29.0M | +30.21% |
| Q2 2023 | 2023-06-30 | $132.7M | $36.7M | +38.26% |
| Q1 2023 | 2023-03-31 | $136.8M | $32.1M | +30.60% |
| Q4 2022 | 2022-12-31 | $95.8M | −$19.8M | −17.09% |
| Q3 2022 | 2022-09-30 | $96.1M | −$27.9M | −22.48% |
| Q2 2022 | 2022-06-30 | $96.0M | $47.0M | +95.97% |
| Q1 2022 | 2022-03-31 | $104.8M | $49.6M | +90.06% |
| Q4 2021 | 2021-12-31 | $115.5M | $76.8M | +198.34% |
| Q3 2021 | 2021-09-30 | $123.9M | $82.3M | +197.62% |
| Q2 2021 | 2021-06-30 | $49.0M | $1.4M | +3.01% |
| Q1 2021 | 2021-03-31 | $55.1M | $681,000 | +1.25% |
| Q4 2020 | 2020-12-31 | $38.7M | $2.5M | +7.01% |
| Q3 2020 | 2020-09-30 | $41.6M | −$2.1M | −4.82% |
| Q2 2020 | 2020-06-30 | $47.6M | −$1.2M | −2.46% |
| Q1 2020 | 2020-03-31 | $54.4M | $4.5M | +9.08% |
| Q4 2019 | 2019-12-31 | $36.2M | −$16.6M | −31.39% |
| Q3 2019 | 2019-09-30 | $43.7M | −$16.0M | −26.82% |
| Q2 2019 | 2019-06-30 | $48.8M | −$19.5M | −28.61% |
| Q1 2019 | 2019-03-31 | $49.9M | −$28.6M | −36.39% |
| Q4 2018 | 2018-12-31 | $52.7M | −$36.6M | −40.97% |
| Q3 2018 | 2018-09-30 | $59.8M | −$34.7M | −36.74% |
| Q2 2018 | 2018-06-30 | $68.3M | $6.8M | +11.12% |
| Q1 2018 | 2018-03-31 | $78.5M | $12.7M | +19.37% |
| Q4 2017 | 2017-12-31 | $89.4M | $8.8M | +10.97% |
| Q3 2017 | 2017-09-30 | $94.5M | $8.6M | +9.96% |
| Q2 2017 | 2017-06-30 | $61.5M | −$39.0M | −38.83% |
| Q1 2017 | 2017-03-31 | $65.7M | −$49.4M | −42.90% |
| Q4 2016 | 2016-12-31 | $80.5M | −$49.2M | −37.90% |
| Q3 2016 | 2016-09-30 | $85.9M | −$55.4M | −39.22% |
| Q2 2016 | 2016-06-30 | $100.5M | −$52.6M | −34.36% |
| Q1 2016 | 2016-03-31 | $115.1M | $55.2M | +92.18% |
| Q4 2015 | 2015-12-31 | $129.7M | $109.0M | +528.15% |
| Q3 2015 | 2015-09-30 | $141.4M | — | — |
| Q2 2015 | 2015-06-30 | $153.1M | — | — |
| Q1 2015 | 2015-03-31 | $59.9M | — | — |
| Q4 2014 | 2014-12-31 | $20.6M | — | — |
aTYR PHARMA total assets trends
Over the last five fiscal years, aTYR PHARMA's total assets increased from $38.7M to $93.0M, a change of $54.3M. The latest reported quarter, Q2 2026, shows $69.8M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review aTYR PHARMA source filings ↗